Nanoviricides to restart Ebola program


NanoViricides (NYSEMKT:NNVC) announces that it will restart its Ebola drug development program in light of the persistent outbreak in West Africa. CEO Eugene Seymour, M.D., Ph.D, says, "We are happy to restart the Ebola program considering the public health impact of the Ebola virus infection. We are in a strong financial position now, enabling us to work on this project while we continue to advance our FluCide and DengueCide therapies further towards clinical trials. We hope to create highly effective drugs against Ebola similar to what we have achieved with our FluCide Influenza drug candidate."

From other sites
Comments (3)
  • rambler1
    , contributor
    Comments (976) | Send Message
     
    What a bunch of nonsense just to goose the stock. Maybe they discover the cure tomorrow (sarcasm).
    4 Aug 2014, 07:33 AM Reply Like
  • NNVC-archive-dot-org
    , contributor
    Comments (5) | Send Message
     
    Right after they finish with their rabies treatment, their herpes treatment, and all the other ones they were "developing" until they could get a couple press releases out.
    4 Aug 2014, 02:44 PM Reply Like
  • ellaruth
    , contributor
    Comments (992) | Send Message
     
    NanoViricides has the technology to make a difference.
    Our nation and the world are introuble. Dr Diwan and Dr Seymour have the ability to help President Obama and Ms Hamburg
    5 Aug 2014, 11:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs